Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops therapies for serious respiratory conditions. Its primary product candidate is Haduvio, an oral extended-release formulation of nalbuphine that targets opioid receptors in the central and peripheral nervous systems to inhibit the cough reflex. The company focuses its drug development activities on treating chronic cough in individuals diagnosed with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. Its prospective patient base consists of individuals suffering from severe, persistent coughing associated with these chronic pulmonary disorders.

The company conducts its operations within the United States, targeting patient populations nationwide, including approximately 150,000 domestic individuals affected by idiopathic pulmonary fibrosis. Trevi Therapeutics contracts with external third parties for research, clinical trials, and active ingredient manufacturing. The business is incorporated in Delaware and maintains its principal executive offices in New Haven, Connecticut.

Summary of the business section of Trevi Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 34 employees, with 21 employees engaged in research and development and the remaining 13 engaged in general management and administration, including finance and commercial.”